Stocks · Health care · Pharmaceutical Preparations

Contineum Therapeutics, Inc.

CTNM Clue Score32
United States Fiscal year ends December CIK 0001855175 Results filed 3 Nov 2026

What the insiders did No buying or selling

By person

3 insiders · 0 transactions
0.4×

Carmine N. Stengone holds only 0.4 times base salary in stock. $283.33K of shares against $655.62K in salary for 2025.

Salary from the company's own proxy. The shares are what Carmine N. Stengone last reported holding, valued at $16.46, the price Class A Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Daniel S. Lorrain
Chief Scientific Officer
—
—
—
135,202
$2.22M
−23.1%
Carmine N. Stengone
CEO and President
—
—
—
17,217
$283.33K
0.0%
Tim Watkins
CMO & Head of Development
—
—
—
8,961
$147.47K
0.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.